生物来源
mouse
质量水平
抗体形式
purified antibody
抗体产品类型
primary antibodies
克隆
PAb240, monoclonal
形式
liquid
包含
≤0.1% sodium azide as preservative
种属反应性
mouse, rat, human, chicken, hamster, bovine
请勿与下列物质发生反应
Xenopus
制造商/商品名称
Calbiochem®
储存条件
do not freeze
同位素/亚型
IgG1
运输
wet ice
储存温度
2-8°C
靶向翻译后修饰
unmodified
基因信息
human ... TP53(7157)
一般描述
在非变性条件下,通过免疫沉淀、免疫荧光和流式细胞术识别~53 kDa突变型p53蛋白。在变性条件下通过免疫印迹和石蜡切片识别突变型和野生型p53。
该抗p53(Ab-3)(突变体)小鼠mAb(PAb240)经验证可用于FC、冰冻切片、凝胶阻滞、免疫印迹、IF、IP和石蜡切片,以检测p53(Ab-3)(突变体)。
通过用指定的免疫原免疫BALB/c小鼠并将脾细胞与SP2小鼠骨髓瘤细胞融合而产生的纯化小鼠单克隆抗体(请参阅应用参考)。在非变性条件下,识别~53 kDa突变型p53蛋白。在变性条件下识别突变型和野生型p53蛋白。
免疫原
人
由p53的氨基酸14-389与β-半乳糖苷酶融合而成的重组蛋白
表位:氨基酸213-217内
应用
流式细胞仪(1-20 µg/ml)
冷冻切片(10 µg/ml)
凝胶阻滞(请参阅备注)
免疫印迹(5 µg/ml)
免疫荧光(1-20 µg/ml,请参阅应用参考)
免疫沉淀(每个样品1 µg)
石蜡部分(请参阅应用参考)
冷冻切片(10 µg/ml)
凝胶阻滞(请参阅备注)
免疫印迹(5 µg/ml)
免疫荧光(1-20 µg/ml,请参阅应用参考)
免疫沉淀(每个样品1 µg)
石蜡部分(请参阅应用参考)
包装
请参考特定浓度批号的标签。
警告
毒性:标准处理(A)
外形
溶于50 mM磷酸钠缓冲液(pH 7.5),含0.2%明胶。
分析说明
阳性对照
A431、Hs27(野生型p53)或SK-BR-3细胞或乳腺癌组织
A431、Hs27(野生型p53)或SK-BR-3细胞或乳腺癌组织
阴性对照
SK-OV-3细胞
SK-OV-3细胞
其他说明
El-Deiry, W.S., et al. 1994.Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994.Cancer Res.54, 4855.
Barak, Y., et al. 1993.EMBO J.12, 461.
Kastan, M.B., et al. 1992.Cell71, 587.
Kuerbitz, S.J.1992.Proc.Natl.Acad.Sci. USA89, 7491.
Lane, D.P.1992.Nature358, 15.
Kastan, M.B., et al. 1991.Cancer Res.51, 6304.
Greenblatt, M.S., et al. 1994.Cancer Res.54, 4855.
Barak, Y., et al. 1993.EMBO J.12, 461.
Kastan, M.B., et al. 1992.Cell71, 587.
Kuerbitz, S.J.1992.Proc.Natl.Acad.Sci. USA89, 7491.
Lane, D.P.1992.Nature358, 15.
Kastan, M.B., et al. 1991.Cancer Res.51, 6304.
在非变性条件下(免疫沉淀、免疫荧光和冰冻切片),抗p53(Ab-3)不识别正常(野生型)p53蛋白;它识别通过激活突变或变性暴露的表位。在变性方案(免疫印迹和石蜡切片)中,抗p53(Ab-3)将识别突变型和野生型p53。不会识别某些具有RHSVV表位突变的p53分子,但会与具有RHSVV表位的TFIIIA反应。对于凝胶阻滞分析,使用目录编号OP29L,复溶于100 µl缓冲液中。在单个系统中,应对抗体进行滴定以获得最佳结果。
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Not finding the right product?
Try our 产品选型工具.
WGK
nwg
闪点(°F)
Not applicable
闪点(°C)
Not applicable
OncoTargets and therapy, 10, 137-144 (2017-01-06)
Epigallocatechin-3-gallate (EGCG) is an antioxidant agent derived from green tea. Because it has chemopreventive and anti-invasive effect against various cancer cells, EGCG can be used to inhibit proliferation and invasion of cholangiocarcinoma (CCA) cells. The anticancer effects of EGCG were
International journal of molecular sciences, 22(16) (2021-08-28)
As the most common gene mutation found in cancers, p53 mutations are detected in up to 96% of high-grade serous ovarian carcinoma (HGSOC). Meanwhile, mutant p53 overexpression is known to drive oncogenic phenotypes in cancer patients and to sustain the
Histochemistry and cell biology, 123(3), 263-273 (2005-03-03)
The cytoskeleton of senescent cells was systematically studied using senescent and young fibroblasts. In the cell senescence, skin fibroblasts extraordinarily produced vimentin in contrast to actin and tubulin, which were down-regulated. Among the focal adhesion proteins, paxillin and c-Src decreased
Cancer biology & therapy, 14(3), 246-253 (2013-01-08)
Breast cancer can be classified into different molecular subtypes with varying clinical and pathological characteristics. The basal-like breast cancer subtype represents one of the most aggressive and lethal types of breast cancer, and due to poor mechanistic understanding, it lacks
Neoplasia (New York, N.Y.), 15(9), 1018-1027 (2013-09-13)
Lung cancer is the leading cause of cancer deaths worldwide. Expression of the p53 tumor suppressor protein is frequently altered in tobacco-associated lung cancers. We studied chemopreventive effects of p53-modulating agents, namely, CP-31398 and Prima-1, on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung adenoma
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门